Novel pan-histone-deacetylase inhibitor with alkylating activity

Neurotoxin, acting via vanilloid receptors of sensory nerves

Novel hepcidin antagonist

hPPAR

Dual PPA

hPPAR-pan agonist

Anti-arrhythmia agent

Novel AC220-based FLT3 degrader

Novel AC220-based FLT3 degrader

The first small molecule degrader, inducing anaplastic lymphoma kinase (ALK) degradation, including in non-small-cell lung cancer (NSCLC), anaplastic large-cell lymphoma (ALCL), and neuroblastoma (NB) cell lines

The first small molecule degrader, inducing anaplastic lymphoma kinase (ALK) degradation, including in non-small-cell lung cancer (NSCLC), anaplastic large-cell lymphoma (ALCL), and neuroblastoma (NB) cell lines

Novel Insulin Receptor Modulator

Novel Toll-Like Receptor 4 (TLR4) Inhibitor

Novel potent and selective dual TLR7/8 inhibitor

Novel toll-like receptor 8 (TLR8) inhibitor, potently and selectively reducing TLR8-mediated signaling

The first small molecule inhibitor of translesion synthesis (TLS) that target Rev1-CT

Potent histone methyltransferase inhibitor with rapid antimalarial activity against all blood stage forms in Plasmodium falciparum

Novel inhibitor of both JAK/STAT and proteasome activities, inducing cell death in myeloma cells

Novel inhibitor of plasminogen activator inhibitor-1 (PAI-1)

Penem beta-lactam antibiotic

Novel protease inhibitor (PI) against a variety of HIV-1 strains, including multi-PI-resistant strains, and may be less likely to generate resistance, also showing antiviral avtivity as a potential treatment for COVID-19 caused by SARS-CoV-2

Dual Inhibitor of SIRT2 Deacetylase and Defatty-Acylase Activities